Gilead Sciences: Can Earnings Cure What Ails It?

Gilead Sciences (GILD) reports its financial results after today’s close today. Does it have the perfect prescription to cure its recent weakness? Bloomberg Shares of Gilead Sciences have dropped 11% during the past three months, as concerns about the cost of its hepatitis-C drug Sovaldi have hit the headlines. That makes it one of the worst [...]